CRBP Straddle Strategy
CRBP (Corbus Pharmaceuticals Holdings, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
CRBP (Corbus Pharmaceuticals Holdings, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $180.8M, a beta of 2.56 versus the broader market, a 52-week range of 7.12-20.56, average daily share volume of 421K, a public-listing history dating back to 2014, approximately 36 full-time employees. These structural characteristics shape how CRBP stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.56 indicates CRBP has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a straddle on CRBP?
A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.
CRBP snapshot
As of August 14, 2026, spot at $10.11, ATM IV 111.50%, IV rank 25.46%, expected move 31.97%. The straddle on CRBP below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this straddle structure on CRBP specifically: CRBP IV at 111.50% is on the cheap side of its 1-year range, which favors premium-buying structures like a CRBP straddle, with a market-implied 1-standard-deviation move of approximately 31.97% (roughly $3.23 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CRBP expiries trade a higher absolute premium for lower per-day decay. Position sizing on CRBP should anchor to the underlying notional of $10.11 per share and to the trader's directional view on CRBP stock.
CRBP straddle setup
The CRBP straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CRBP at $10.11 on that close, the first option leg uses a $10.11 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CRBP chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CRBP shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $10.11 | N/A |
| Buy 1 | Put | $10.11 | N/A |
CRBP straddle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.
CRBP straddle payoff curve
Modeled P&L at expiration across a range of underlying prices for the straddle on CRBP. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use straddle on CRBP
Straddles on CRBP are pure-volatility plays that profit from large moves in either direction; traders typically buy CRBP straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
CRBP thesis for this straddle
The market-implied 1-standard-deviation range for CRBP extends from approximately $6.88 on the downside to $13.34 on the upside. A CRBP long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current CRBP IV rank near 25.46% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CRBP at 111.50%. As a Healthcare name, CRBP options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CRBP-specific events.
CRBP straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CRBP positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CRBP alongside the broader basket even when CRBP-specific fundamentals are unchanged. Always rebuild the position from current CRBP chain quotes before placing a trade.
Frequently asked questions
- What is a straddle on CRBP?
- A straddle on CRBP is the straddle strategy applied to CRBP (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With CRBP stock at $10.11 on the most recent close, the strikes shown on this page are snapped to the nearest listed CRBP chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are CRBP straddle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the CRBP straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 111.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CRBP straddle?
- The breakeven for the CRBP straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The CRBP market-implied 1-standard-deviation expected move in the same options snapshot is approximately 31.97%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a straddle on CRBP?
- Straddles on CRBP are pure-volatility plays that profit from large moves in either direction; traders typically buy CRBP straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
- How does current CRBP implied volatility affect this straddle?
- CRBP ATM IV is at 111.50% with IV rank near 25.46%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.